The Pill That's Coming for J&J's Lung Cancer Throne
Cullinan and Taiho's oral cancer drug zipalertinib just posted a six-month survival advantage over chemo alone in a rare form of lung cancer, and the numbers look better than J&J's market-leading Rybrevant. The catch? The most important data point is still cooking.
Six Extra Months of Life, Bottled in a Tablet
Imagine you're diagnosed with a rare, aggressive form of lung cancer. Your doctor tells you there's basically one good first-line treatment on the market, and it's an IV infusion from one of the biggest pharma companies on Earth. Now imagine someone shows up with a pill that might work even better.
That's roughly what just happened in the world of EGFR exon 20 insertion non-small cell lung cancer (NSCLC), a mutation found in roughly 1% to 2% of all lung cancers. On September 13, Cullinan Therapeutics and Taiho Oncology dropped Phase 3 results for zipalertinib that have the potential to reshape how doctors treat this disease. Combined with standard platinum-based chemotherapy, their oral drug cut the risk of cancer progression in half compared to chemo alone.
The headline number: patients on zipalertinib lived 14.5 months without their cancer getting worse, versus 8.5 months for those on chemotherapy by itself. That's a six-month improvement, which in oncology is the kind of result that makes physicians sit up in their chairs.
Why This Corner of Lung Cancer Matters
EGFR exon 20 insertions are a frustrating quirk of cancer biology. Most EGFR mutations in lung cancer respond well to targeted pills called TKIs (tyrosine kinase inhibitors). Think of EGFR as a lock on the surface of cancer cells. Standard TKIs are keys that fit the common lock shapes. But exon 20 insertions change the shape of the lock just enough that those standard keys don't work; response rates to first- and second-generation EGFR drugs are less than 10%.
For years, patients with this mutation were stuck with plain old chemotherapy. The median overall survival in some real-world studies hovered around 17 months. Not great for a cancer that tends to show up in younger, never-smoking patients who feel like they should have better options.
Then Johnson & Johnson's amivantamab (Rybrevant) arrived. Combined with carboplatin and pemetrexed (a chemo cocktail), it became the first-line standard of care. The PAPILLON trial showed a median progression-free survival (PFS) of for the combo. It was a genuine breakthrough: the first targeted front-line option for these patients.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
11.4 months
But amivantamab is an IV antibody, not a pill. And now zipalertinib is knocking on the door with a PFS number that, at least on paper, looks noticeably better.
The REZILIENT3 Results, Decoded
The Phase 3 trial, called REZILIENT3, enrolled previously untreated patients with locally advanced or metastatic EGFR exon 20 insertion NSCLC from sites around the world. Patients were randomized to receive either zipalertinib plus platinum-based chemo or chemo alone.
The primary endpoint was PFS, measured by independent reviewers who didn't know which arm patients were on. The trial nailed it. The hazard ratio came in at 0.50 (95% CI: 0.34–0.73, p=0.00015), which translates to a 50% reduction in the risk of disease progression or death. In clinical trial speak, that's a clean, convincing win.
Now for the caveat. Overall survival (OS), the gold-standard measure of whether a cancer drug actually helps people live longer, is still cooking. The interim OS hazard ratio was 0.72, which trends in the right direction, but the analysis was only 30% mature. Think of it like checking a soufflé through the oven window at the halfway mark: it looks promising, but you can't call it done. The Independent Data Monitoring Committee was confident enough to recommend unblinding the study, and follow-up will continue.
The J&J Showdown Nobody Can Ignore
Let's address the elephant in the room. Zipalertinib's 14.5-month PFS versus amivantamab's 11.4-month PFS is a comparison every oncologist and investor will make, even though they really shouldn't (at least not definitively). These numbers come from different trials, with different patient populations, different protocols, and different control arms. Cross-trial comparisons are the fantasy football of oncology: fun to argue about, but not the same as head-to-head proof.
That said, there are practical advantages worth noting. Zipalertinib is an oral drug. Amivantamab requires IV infusions. For patients and clinics already stretched thin, the convenience of a pill matters. And in a disease where quality of life is precious, how you take a drug can be almost as important as how well it works.
Amivantamab isn't going anywhere, though. J&J has deep commercial infrastructure, multiple approved EGFR indications globally, and years of real-world data. Plus, sunvozertinib (from Dizal Pharma) picked up accelerated U.S. approval in July 2025 as an oral option for patients who've already been through platinum chemo. The exon 20 insertion space went from a therapeutic desert to a three-way competitive scramble in less than two years.
Meanwhile, mobocertinib, Takeda's earlier oral entry, has exited the U.S. market after its Phase 3 program fell short. One fewer competitor at the table, but the remaining players are stronger for it.
What Wall Street Is Thinking
Cullinan Therapeutics (ticker: CGEM) now has a genuine late-stage asset with a clean Phase 3 win. The company's collaboration with Taiho gives it a 50/50 U.S. profit share and up to $130 million in regulatory milestone payments. The FDA accepted zipalertinib's NDA in April 2026, with a PDUFA decision date of February 27, 2027. That NDA is based on the Phase 2b REZILIENT1 data in previously treated patients, with the REZILIENT3 results now adding a powerful first-line dataset.
For investors, the bull case is straightforward: zipalertinib has the best PFS data in first-line exon 20 insertion NSCLC (cross-trial caveats aside), it's an oral drug, and it has a clear path to approval. The bear case centers on that immature OS data. Without a confirmed survival benefit, some payers and physicians might hesitate to switch from a proven amivantamab regimen.
The FDA granted Breakthrough Therapy designation back in January 2022, so the regulatory relationship has been warm for a while. Taiho completed its rolling NDA submission in Q1 2026, and the clock is now ticking toward that February 2027 decision.
The Bottom Line
Six months of additional progression-free survival is meaningful when your baseline expectation is measured in single-digit months. Zipalertinib won't replace amivantamab overnight, and the overall survival story still needs time to develop. But for a patient population that was essentially untreatable with targeted therapy just five years ago, having multiple competitive options is the kind of problem oncology should want to have.
The exon 20 insertion market is small (roughly 1% to 2% of all NSCLC), but it's becoming one of the most interesting competitive battlegrounds in lung cancer. Cullinan and Taiho just fired a serious shot. Whether it lands a knockout punch depends on what those survival numbers look like when the soufflé is actually done.
Clinical & Regulatory
4 min read
Two Shots a Year. Two Infections Out of 2,180 People.
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.
